CFH and hepatocellular carcinoma: With the use of a recombinant anti‐CFH antibody which has been shown to cause complement activation (Bushey et al., 2016), the effect of MHCC97L‐EVs on HCC cell migration and invasion in the presence of a specific anti‐CFH antibody was studied.